Log in to search using one of your social media accounts:

 

Motor system pathology in psychosis - Walther S, Mittal VA.
PURPOSE OF REVIEW: Motor abnormalities are an intrinsic feature of psychosis. Neurological soft signs, Parkinsonism, dyskinesia, and other motor phenomena are frequently observed in subjects at clinical or genetic risk for psychosis as well as first-episod... (Source: SafetyLit)
Source: SafetyLit - November 6, 2017 Category: International Medicine & Public Health Tags: Ergonomics, Human Factors, Anthropometrics, Physiology Source Type: news

FDA approves pivotal trial for Insightec ’ s Exablate Neuro in Parkinson ’ s
Insightec said today that it won FDA approval for a pivotal trial of its Exablate Neuro device in treating refractory Parkinson’s disease. Haifa, Israel-based Insightec said the the study will evaluate using Exablate Neuro’s MR-guided focused ultrasound to ablate portions of the globus pallidus in the brain, which helps regulate voluntary movement. The trial, led by principal investigator Dr. Howard Eisenberg of the University of Maryland, aims to treat dyskinesia in patients with advanced Parkinson’s who have not responded to medication. “Insightec remains committed to advancing research to ex...
Source: Mass Device - October 25, 2017 Category: Medical Devices Authors: Brad Perriello Tags: Clinical Trials Food & Drug Administration (FDA) Imaging Radiosurgery INSIGHTEC Source Type: news

Medical News Today: What you need to know about dyskinesia
We look at dyskinesia, including the main symptoms and treatment options. Learn more about this condition that results in involuntary movements here. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - October 19, 2017 Category: Consumer Health News Tags: Neurology / Neuroscience Source Type: news

Neurocrine Announces FDA Approval of 80 mg INGREZZA(R) (valbenazine) Capsules for the Treatment of Adults with Tardive Dyskinesia (TD)
First and only TD therapy taken as one capsule, once per day; new 80 mg capsule expected to be available for patients within two weeks INBRACE™ program offers patients access to treatment and patient assistance SAN DIEGO, Oct. 5, 2017 -- (Healthcare ... Biopharmaceuticals, Neurology, FDA Neurocrine Biosciences, INGREZZA, valbenazine, tardive dyskinesia (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - October 5, 2017 Category: Pharmaceuticals Source Type: news

ICER publishes draft report on 3  tardive dyskinesia therapies
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - October 1, 2017 Category: Drugs & Pharmacology Source Type: news

9 Brand New Drugs for Primary Care
COPD … nasal polyps.. gout …. dyskinesia in Parkinson Disease: here’s a brief look at new drugs for these and other disorders coming your way. (Source: ConsultantLive)
Source: ConsultantLive - September 28, 2017 Category: Internal Medicine Authors: Susan Kweskin Tags: COPD Gout Source Type: news

Systematic review of interventions for treating or preventing antipsychotic-induced tardive dyskinesia
Antipsychotic medication can cause tardive dyskinesia (TD) – late-onset, involuntary, repetitive movements, often involving the face and tongue. TD occurs in> 20% of adults taking antipsychotic medication (first-generation antipsychotics for> 3 months), with this proportion increasing by 5% per year among those who continue to use these drugs. The incidence of TD among those taking newer antipsychotics is not different from the rate in people who have used older-generation drugs in moderate doses. Studies of TD have previously been found to be limited, with no treatment approach shown to be effective. To summ...
Source: Current Awareness Service for Health (CASH) - September 25, 2017 Category: Consumer Health News Source Type: news

Second Tardive Dyskinesia Drug Okayed
(MedPage Today) -- Deutetrabenazine (Austedo) joins valbenazine (Ingrezza) in TD indication (Source: MedPage Today Neurology)
Source: MedPage Today Neurology - August 31, 2017 Category: Neurology Source Type: news

FDA OKs Deutetrabenazine (Austedo) for Tardive Dyskinesia FDA OKs Deutetrabenazine (Austedo) for Tardive Dyskinesia
The drug was also approved for chorea associated with Huntington's disease earlier in this year.FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 31, 2017 Category: Consumer Health News Tags: Neurology & Neurosurgery News Alert Source Type: news

Teva Announces FDA Approval of Austedo (deutetrabenazine) Tablets for the Treatment of Tardive Dyskinesia in Adults
JERUSALEM--(BUSINESS WIRE) August 30, 2017 --Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that the U.S. Food and Drug Administration (FDA) has approved Austedo (deutetrabenazine) tablets for the treatment of tardive... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - August 30, 2017 Category: Drugs & Pharmacology Source Type: news

FDA Okays Parkinson's Dyskinesia Drug
(MedPage Today) -- Immediate-release version already used off-label for condition (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - August 25, 2017 Category: American Health Source Type: news

FDA Clears First Drug for Parkinson's Dyskinesia FDA Clears First Drug for Parkinson's Dyskinesia
The FDA has approved the first drug for treatment of dyskinesia in patients with Parkinson's disease dyskinesia, fulfilling an"unmet need" in PD management, experts say.FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 25, 2017 Category: Consumer Health News Tags: Neurology & Neurosurgery News Alert Source Type: news

FDA Approves Gocovri (amantadine) for the Treatment of Dyskinesia in Parkinson's Disease Patients
EMERYVILLE, Calif., Aug. 24, 2017 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that the U.S. Food and Drug Administration (FDA) has approved Gocovri (amantadine) extended release capsules (previously ADS-5102) for... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - August 24, 2017 Category: Drugs & Pharmacology Source Type: news

Adamas Pharma secures approval for Parkinson's dyskinesia drug
(Reuters) - The U.S. Food and Drug Administration (FDA) said it had approved Adamas Pharmaceuticals Inc's treatment for a side effect caused by a commonly prescribed Parkinson's drug, sending the shares of the drugmaker soaring in after-market trading. (Source: Reuters: Health)
Source: Reuters: Health - August 24, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

Diabetes drug may be helpful for Parkinson's disease
Conclusion This research shows some interesting early findings, though the magnitude of effect was very small compared to the improvements in symptoms with current dopaminergic drugs. The study was well conducted but did have some limitations: The number of people taking part was quite small. This may have meant it was hard to detect any other benefits or harms of taking the drug other than the effects on motor scores. The period of time people were given the drug and followed up meant that longer-term effects could not be measured. The benefit of the drug observed so far might not be big enough to make a difference ...
Source: NHS News Feed - August 4, 2017 Category: Consumer Health News Tags: Neurology Source Type: news

Drug Eases Tardive Dyskinesia Linked to Antipsychotic Use Drug Eases Tardive Dyskinesia Linked to Antipsychotic Use
Deutetrabenazine significantly reduced abnormal involuntary movements in patients with tardive dyskinesia caused by antipsychotic drugs in a phase 3 study.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 5, 2017 Category: Consumer Health News Tags: Psychiatry News Source Type: news

Second Tardive Dyskinesia Drug Works (CME/CE)
(MedPage Today) -- Deutetrabenazine in line to be second VMAT-2 inhibitor OK'd for the condition (Source: MedPage Today Psychiatry)
Source: MedPage Today Psychiatry - July 1, 2017 Category: Psychiatry Source Type: news

Extended-Release Amantadine Effective for Dyskinesia in PD Extended-Release Amantadine Effective for Dyskinesia in PD
A phase 3 study shows a once-daily formulation of amantadine is superior to placebo in reducing severity and duration of levodopa-induced dyskinesia in patients with Parkinson's.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 21, 2017 Category: Consumer Health News Tags: Neurology & Neurosurgery News Source Type: news

New Amantadine Pill Cuts Dyskinesia in Parkinson's (CME/CE)
(MedPage Today) -- But questions about cost-effectiveness remain (Source: MedPage Today State Required CME)
Source: MedPage Today State Required CME - June 12, 2017 Category: Consumer Health News Source Type: news

Drug reduces dyskinesia, 'off' times in Parkinson's patients
(Reuters Health) - An experimental extended-release version of the drug amantadine can reduce the duration of the involuntary dancing-like movements seen in people whose long-term use of levodopa has kept their Parkinson ’s disease under control. (Source: Reuters: Health)
Source: Reuters: Health - June 12, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

New Drug Safe, Effective for Tardive Dyskinesia New Drug Safe, Effective for Tardive Dyskinesia
Phase 3 trials showed improved movement and quality-of-life scores for deutetrabenazine-treated patients with tardive dyskinesia, leading the FDA to grant priority review and an August 30 target date.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 6, 2017 Category: Consumer Health News Tags: Psychiatry News Source Type: news

Valbenazine for Tardive Dyskinesia Tolerated Long-Term
(MedPage Today) -- Only 15% of patients discontinued tx over 1 year due to adverse events (Source: MedPage Today Meeting Coverage)
Source: MedPage Today Meeting Coverage - May 29, 2017 Category: General Medicine Source Type: news

Valbenazine Approval Highlights Lessons for Researchers Valbenazine Approval Highlights Lessons for Researchers
A New England Journal of Medicine editorial notes that the recent FDA approval of valbenazine for tardive dyskinesia shows how to effectively and quickly develop a much-needed treatment.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - May 11, 2017 Category: Consumer Health News Tags: Neurology & Neurosurgery News Source Type: news

NeuroBreak: $63,000 Question for Tardive Dyskinesia; Sacco Leads AAN
(MedPage Today) -- News and commentary from the world of neurology and neuroscience (Source: MedPage Today Psychiatry)
Source: MedPage Today Psychiatry - May 2, 2017 Category: Psychiatry Source Type: news

ICER to review treatments for tardive dyskinesia
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - May 1, 2017 Category: Drugs & Pharmacology Source Type: news

Neurocrine Announces INGREZZA(TM) Long-Term Safety and Efficacy Data to be Presented at the 2017 American Academy of Neurology Annual Meeting
Additional results from largest ever clinical program in tardive dyskinesia to be highlighted as platform and poster presentations SAN DIEGO, April 21, 2017 -- (Healthcare Sales & Marketing Network) -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announ... Biopharmaceuticals, Neurology Neurocrine Biosciences, INGREZZA, valbenazine, tardive dyskinesia (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - April 21, 2017 Category: Pharmaceuticals Source Type: news

Ingrezza (valbenazine) for the Treatment of Tardive Dyskinesia
Ingrezza (valbenazine) is first and only US Food and Drug Administration (FDA) approved vesicular monoamine transporter 2 (VMAT2) inhibitor indicated for the treatment of adults with Tardive dyskinesia (TD). (Source: Drug Development Technology)
Source: Drug Development Technology - April 17, 2017 Category: Pharmaceuticals Source Type: news

First Drug Approved for Tardive Dyskinesia (FREE)
By Amy Orciari Herman Edited by Susan Sadoughi, MD, and Richard Saitz, MD, MPH, FACP, DFASAM The FDA has approved valbenazine (Ingrezza) capsules to treat adults with tardive dyskinesia. The vesicular monoamine … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - April 13, 2017 Category: Primary Care Source Type: news

FDA Approves First Drug for Treatment of Tardive Dyskinesia
Ingrezza (valbenazine) capsules approved for treatment of adults with tardive dyskinesia (Source: The Doctors Lounge - Psychiatry)
Source: The Doctors Lounge - Psychiatry - April 13, 2017 Category: Psychiatry Tags: Family Medicine, Geriatrics, Internal Medicine, Neurology, Nursing, Pharmacy, Psychiatry, Institutional, Source Type: news

US FDA approves Neurocrine ’s Ingrezza capsules to treat tardive dyskinesia
The US Food and Drug Administration (FDA) has approved Neurocrine Biosciences ’ Ingrezza (valbenazine) capsules to treat adults with tardive dyskinesia (TD). (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - April 12, 2017 Category: Pharmaceuticals Source Type: news

1st Drug for Tardive Dyskinesia Approved
Condition characterized by involuntary movement of the jaw, lips and tongue Source: HealthDay Related MedlinePlus Pages: Medicines, Movement Disorders (Source: MedlinePlus Health News)
Source: MedlinePlus Health News - April 12, 2017 Category: Consumer Health News Source Type: news

1st Drug for Tardive Dyskinesia, Ingrezza (Valbenazine), Approved
WEDNESDAY, April 12, 2017 -- Ingrezza (valbenazine), the first drug to treat adults with the neurological disorder tardive dyskinesia, has been approved by the U.S. Food and Drug Administration. The disorder is characterized by repetitive... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - April 12, 2017 Category: Journals (General) Source Type: news

First Drug for Tardive Dyskinesia, Ingrezza (valbenazine), Approved
WEDNESDAY, April 12, 2017 -- Ingrezza (valbenazine), the first drug to treat adults with the neurological disorder tardive dyskinesia, has been approved by the U.S. Food and Drug Administration. The disorder is characterized by repetitive... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - April 12, 2017 Category: Journals (General) Source Type: news

FDA approves first drug to treat tardive dyskinesia
The U.S. Food and Drug Administration approved Ingrezza (valbenazine) capsules to treat adults with tardive dyskinesia. This is the first drug approved by the FDA for this condition. Tardive dyskinesia is a neurological disorder characterized by repetitive involuntary movements, usually of the jaw, lips and tongue, such as grimacing, sticking out the tongue and smacking the lips. (Source: World Pharma News)
Source: World Pharma News - April 12, 2017 Category: Pharmaceuticals Tags: Featured FDA Regulatory Affairs Source Type: news

FDA Approves Valbenazine (Ingrezza) for Tardive Dyskinesia FDA Approves Valbenazine (Ingrezza) for Tardive Dyskinesia
The US Food and Drug Administration has approved valbenazine, the first medication for the treatment of tardive dyskinesia.FDA Approvals (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - April 12, 2017 Category: Neurology Tags: Neurology & Neurosurgery News Alert Source Type: news

Neurocrine Biosciences gets FDA's OK for movement disorder drug
(Reuters) - The U.S. Food and Drug Administration approved Neurocrine Biosciences Inc's drug to treat tardive dyskinesia, a side effect of antipsychotic medications characterized by uncontrolled movements of the face and body, the company said. (Source: Reuters: Health)
Source: Reuters: Health - April 12, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

FDA Okays First Tardive Dyskinesia Drug
(MedPage Today) -- VMAT2 inhibitor diminished abnormal involuntary movements in pivotal trial (Source: MedPage Today Psychiatry)
Source: MedPage Today Psychiatry - April 11, 2017 Category: Psychiatry Source Type: news

FDA approves first drug to treat tardive dyskinesia
The U.S. Food and Drug Administration today approved Ingrezza (valbenazine) capsules to treat adults with tardive dyskinesia. This is the first drug approved by the FDA for this condition. (Source: Food and Drug Administration)
Source: Food and Drug Administration - April 11, 2017 Category: American Health Source Type: news

Neurocrine Announces FDA Approval of Ingrezza (valbenazine) as the First and Only Approved Treatment for Adults with Tardive Dyskinesia (TD)
SAN DIEGO, April 11, 2017 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that the U.S. Food and Drug Administration (FDA) has approved Ingrezza (valbenazine) capsules for the treatment of adults with tardive dyskinesia... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - April 11, 2017 Category: Drugs & Pharmacology Source Type: news

FDA to Expedite Review of Teva Drug for Movement Disorder FDA to Expedite Review of Teva Drug for Movement Disorder
Israel-based Teva Pharmaceutical Industries said on Tuesday the U.S. Food and Drug Administration (FDA) has granted"priority review" for its SD-809 drug to treat tardive dyskinesia with a target date for approval by Aug. 30.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - March 1, 2017 Category: Consumer Health News Tags: Family Medicine/Primary Care News Source Type: news

FDA to expedite review of Teva drug for movement disorder
"There remains a significant unmet medical need in tardive dyskinesia," said Michael Hayden, chief scientific officer at Teva. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - February 28, 2017 Category: Pharmaceuticals Source Type: news

FDA to expedite review of Teva drug for movement disorder
TEL AVIV (Reuters) - Israel-based Teva Pharmaceutical Industries said on Tuesday the U.S. Food and Drug Administration (FDA) has granted "priority review" for its SD-809 drug to treat tardive dyskinesia with a target date for approval by Aug. 30. (Source: Reuters: Health)
Source: Reuters: Health - February 28, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

Poorly tuned neuronal communication may underlie neurological and psychiatric disease
(JCI Journals) In this issue of the JCI, Nils Brose and colleagues at the Max Planck Institute for Experimental Medicine have identified a mutation in a synaptic protein called UNC13 in a patient diagnosed with ASD, hyperactivity, and dyskinesia. Further investigation revealed that the UNC13 mutation disturbs the fine-tuning of neuronal communication at the level of the synapse. (Source: EurekAlert! - Social and Behavioral Science)
Source: EurekAlert! - Social and Behavioral Science - February 13, 2017 Category: Global & Universal Source Type: news

Adamas Announces U.S. FDA Acceptance of ADS-5102 New Drug Application for the Treatment of Levodopa-induced Dyskinesia in Patients with Parkinson's Disease
EMERYVILLE, Calif., Jan. 06, 2017 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for ADS-5102 (amantadine... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - January 6, 2017 Category: Drugs & Pharmacology Source Type: news

Neurocrine Provides Update on FDA Advisory Committee for Ingrezza (valbenazine) for the Treatment of Tardive Dyskinesia
SAN DIEGO, Jan. 5, 2017 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced that the U.S. Food and Drug Administration (FDA), after further review of the Ingrezza (valbenazine) New Drug Application (NDA), has decided to... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - January 5, 2017 Category: Drugs & Pharmacology Source Type: news

Neurocrine Announces FDA Advisory Committee Meeting to Review INGREZZA(TM) (valbenazine) New Drug Application for the Treatment of Tardive Dyskinesia
SAN DIEGO, Nov. 29, 2016 -- (Healthcare Sales & Marketing Network) -- Neurocrine Biosciences, Inc. (NBIX) today announced that the Psychopharmacologic Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) will review data included in the... Biopharmaceuticals, Neurology, FDA Neurocrine Biosciences, INGREZZA, valbenazine, tardive dyskinesia (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - November 30, 2016 Category: Pharmaceuticals Source Type: news

Neurocrine Announces FDA Advisory Committee Meeting to Review Ingrezza (valbenazine) NDA for the Treatment of Tardive Dyskinesia
SAN DIEGO, Nov. 29, 2016 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced that the Psychopharmacologic Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) will review data included in the New Drug... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - November 29, 2016 Category: Drugs & Pharmacology Source Type: news

Once-Daily Oral Med May Reduce Levodopa-Induced Dyskinesia Once-Daily Oral Med May Reduce Levodopa-Induced Dyskinesia
A once-daily extended-release medication may rapidly improve levodopa-induced dyskinesia, a major clinical issue in patients with Parkinson's disease, new research shows.Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - October 6, 2016 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news

Objectively assessed physical activity and its association with balance, physical function and dyskinesia in Parkinson's disease - Nero H, Benka-Wall én M, Franzén E, Conradsson D, Ståhle A, Hagstromer M.
BACKGROUND: The desirable effects of physical activity in individuals with Parkinson's disease are well-known, although according to results from previous studies factors associated with objectively assessed physical activity are not fully investigated. ... (Source: SafetyLit)
Source: SafetyLit - September 10, 2016 Category: Global & Universal Tags: Ergonomics, Human Factors, Anthropometrics, Physiology Source Type: news